On June 23, 2016, Musicki, Branislav published a patent.Safety of (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the patent was Preparation of benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma. And the patent contained the following:
The invention relates to the preparation of benzenesulfonamide derivatives I, wherein q is an integer 0-3; L is a bond, CH2; R1 is alkyl, cycloalkyl, alkenyl, alkyl-cycloalkyl, alkyl-heterocycloalkyl; R2 is H, halogen, alkyl, alkenyl, alkoxy, CN; R3 is H, alkyl, NH2; R4 is H, alkyl, alkoxy, ether, alkyl-amino-alkyl; A1 is substituted amine, O, S, SO, SO2, SO(=NH), CH2, C=C, alkylidene; A2 is bond, S, SO, SO2, sulfonimide, CH(OH), C(=O)O; Q1-Q5 are independently N, alkylidene, and the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma (RORγt). Thus, benzenesulfonamide II was prepared and tested in vitro as inverse agonist of retinoid-related orphan receptor gamma (IC50 = 100 nM – 1 μM). The invention also relates to pharmaceutical compositions comprising such compounds, as well as to the use thereof for the topical and/or oral treatment of RORγt receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Safety of (R)-5-(Hydroxymethyl)oxazolidin-2-one
The Article related to human interleukin acne benzenesulfonamide preparation, cosmetic atopic dermatitis psoriasis antiinflammatory receptor acne benzenesulfonamide preparation, Heterocyclic Compounds (More Than One Hetero Atom): Triazines and other aspects.Safety of (R)-5-(Hydroxymethyl)oxazolidin-2-one
Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem